Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in antisense therapeutics

S T Crooke1

  • 1Isis Pharmaceuticals, Carlsbad, CA 92008, USA.

Hematologic Pathology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Antisense technology shows promise for highly selective pharmacology. This review explores the drug properties of phosphorothioate oligonucleotides, addressing key questions about their potential in medicine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human RNases H.

Methods in enzymology·2001
Same author

Preparation and use of ZFY-6 zinc finger ribonuclease.

Methods in enzymology·2001
Same author

The concept and application of antisense oligonucleotides.

Diseases of the colon and rectum·2001
Same author

Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration.

Biochemical pharmacology·2001
Same author

Potential roles of antisense technology in cancer chemotherapy.

Oncogene·2001
Same author

Investigating the structure of human RNase H1 by site-directed mutagenesis.

The Journal of biological chemistry·2001
Same journal

Hypocellular acute myeloid leukemia: the Rochester (New York) experience.

Hematologic pathology·1995
Same journal

High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.

Hematologic pathology·1995
Same journal

Identification of proerythroblasts in tissue sections of bone marrow.

Hematologic pathology·1995
Same journal

Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia.

Hematologic pathology·1995
Same journal

VLA-4-dependent adhesion in follicular non-Hodgkin's lymphomas.

Hematologic pathology·1995
Same journal

Nonradioactive detection of monoclonal immunoglobulin heavy chain gene rearrangement with PCR-SSCP.

Hematologic pathology·1995
See all related articles

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Biotechnology

Background:

  • Antisense technology enables the development of highly specific pharmacologic agents targeting single isotypes within protein families.
  • Despite its potential, the practical application of antisense technology is limited by questions regarding the drug-like properties of oligonucleotides.

Purpose of the Study:

  • To review recent advancements in understanding the pharmacokinetic, pharmacologic, and toxicologic profiles of phosphorothioate oligonucleotides.
  • To describe progress in oligonucleotide medicinal chemistry and the emergence of novel chemical classes.

Main Methods:

  • Review of recent scientific literature on phosphorothioate oligonucleotides.
  • Analysis of pharmacokinetic, pharmacologic, and toxicologic data.

Related Experiment Videos

  • Discussion of medicinal chemistry innovations in oligonucleotide synthesis.

    • Main Results:

    • Significant progress has been made in defining the properties of phosphorothioate oligonucleotides as drug candidates.
    • A diverse array of new chemical classes of oligonucleotides has been developed through medicinal chemistry efforts.

    Conclusions:

    • Phosphorothioate oligonucleotides are demonstrating improved drug-like properties, addressing previous limitations.
    • Ongoing advancements in oligonucleotide chemistry are expanding the therapeutic potential of antisense technology.